Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2

被引：0
作者：
Kiran Shehzadi
Afsheen Saba
Mingjia Yu
Jianhua Liang
机构：
[1] Beijing Institute of Technology,Key Laboratory of Medical Molecule Science and Pharmaceutical Engineering, Ministry of Industry and Information Technology, School of Chemistry and Chemical Engineering
[2] Yangtze Delta Region Academy of Beijing Institute of Technology,undefined
来源：
Topics in Current Chemistry | 2023年 / 381卷
关键词：
RdRp; SARS-CoV-2; RdRp inhibitors; COVID-19; Therapeutic target;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Exploring the potential clinical targets for attenuating coronavirus disease 2019 (COVID-19) by structure-based drug designing of RdRp inhibitors.RdRp catalytic site and druggable cavities predictions of SARS-CoV-2.Pharmacophoric features and structure–activity relationship analysis of different repurposed therapeutic drugs for COVID-19 against RdRp of SARS-CoV-2.Current treatments are logistically challenging, increasing the need for safe and effective oral therapies.Ongoing global efforts to prevent the spread of COVID-19 disease and the current status of SARS-CoV-2.
引用
收藏
相关论文
共 1103 条
[1]  
Park SE(2020)Epidemiology, virology and clinical features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus disease-19) Pediatr Infect Vaccine 27 1-10
[2]  
Ilyas M(2022)Insighting isatin derivatives as potential antiviral agents against NSP3 of COVID-19 Chem Pap 76 6271-6285
[3]  
Muhammad S(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 497-506
[4]  
Iqbal J(2017)Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies Drugs 77 1935-1966
[5]  
Amin S(2020)Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China J Clin Med 9 575-1115
[6]  
Al-Sehemi AG(2022)The World Health Organization COVID-19 surveillance database Int J Equity Health 21 167-4779
[7]  
Algarni H(2018)Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease MBio 9 1100-1504
[8]  
Alarfaji SS(2020)Mechanisms of SARS-CoV-2 transmission and pathogenesis Trends Immunol 41 4773-1797
[9]  
Alshahrani MY(2020)The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus J Biol Chem 295 1499-464
[10]  
Ayub K(2020)Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir Science 368 1787-64
12345678910